India, July 21 -- Glenmark Specialty S.A. has received approval from the US Food and Drug Administration (FDA) to expand the use of RYALTRIS® Nasal Spray for the treatment of Seasonal Allergic Rhinitis (SAR) in children aged 6 to less than 12 years.
With this approval, RYALTRIS® is now indicated in the United States for both adults and pediatric patients aged 6 years and above, broadening access to the treatment for a younger patient population.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....